Obsidian Therapeutics, Inc. — Form 8-K/A
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 75/100
What the filing says
On August 3, 2026, Obsidian Therapeutics completed a reverse merger with Galera Therapeutics to form a combined company under Obsidian's name. Concurrently, on July 31, 2026, a PIPE financing closed generating $350.0M gross proceeds from qualified institutional buyers and accredited investors purchasing Series C Preferred Stock of Galera. Post-transaction, Legacy Obsidian shareholders own ~51.5% of combined company common stock, Galera shareholders own ~1.3%, and PIPE investors own ~47.2%. The combined entity began trading on Nasdaq under ticker OBX on August 4, 2026.
Why this rating
Merger provides substantial liquidity ($350M) for clinical-stage biotech; extends runway to H2 2028. Significant for standalone Obsidian (cash was $34.4M pre-deal), but dilution and Galera IPR&D expensing are material headwinds. Company remains pre-revenue.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.